Focus: BridgeBio Pharma is a specialty pharmaceutical company focused on genetic disease treatments, particularly rare diseases and oncology, headquartered in Palo Alto with 69 active job openings.
Profile data last refreshed 13h ago · AI intelligence enriched 1mo ago
Hot — 78 jobs added in 30d
Net +24 (78 new, 54 removed). Aggressive expansion phase.
Attractive for commercial and manufacturing professionals seeking rapid growth with a rare-disease focus, but research and development roles face execution risk on unproven pipeline programs.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
First-and-only FDA-approved TTR stabilizer offering 13+ years of exclusivity; core revenue engine supporting commercial infrastructure build-out.
Help build intelligence for BridgeBio Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from BridgeBio Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
How Investors May Respond To BridgeBio Pharma (BBIO) Positive Drug Data - Simply Wall Street
How Investors May Respond To BridgeBio Pharma (BBIO) Positive Drug Data Simply Wall Street
BridgeBio Pharma posts strong Q2 revenue and ad... - Pluang
BridgeBio Pharma posts strong Q2 revenue and ad... Pluang
BridgeBio Pharma reports symptom gains in Phase 3 encaleret trial - Mugglehead Investment Magazine
BridgeBio Pharma reports symptom gains in Phase 3 encaleret trial Mugglehead Investment Magazine
BridgeBio reports improved symptoms in Phase 3 trial of rare-disease drug (BBIO:NASDAQ) - Seeking Alpha
BridgeBio reports improved symptoms in Phase 3 trial of rare-disease drug (BBIO:NASDAQ) Seeking Alpha
FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing - The Globe and Mail
FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing The Globe and Mail
FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing - The Globe and Mail
FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing The Globe and Mail
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
ATTR-CM: What do we know about blood levels of the TTR protein? A discussion with experts.
Safety, Tolerability, Pharmacokinetics, Food Effect of Ribitol, and Its Effect on QTcF in Healthy Adults: First-in-Human, Randomized, Double-Blind (Sponsor Unblinded), Placebo-Controlled Studies.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo